Abstract: This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28− cell and a vitamin D3 analog. This invention also provides methods for generating a tolerogenic antigen-presenting cell, and increasing the expression of ILT3 and/or ILT4 by an antigen-presenting cell. This invention further provides methods for inhibiting the onset of or treating the rejection of an antigenic substance and inhibiting the onset of or treating an autoimmune disease in a subject. This invention further provides methods for treating and preventing AIDS, cancer, and Hepatitis C-related disorders, and for identifying agents useful for such purposes. Finally, this invention provides related compositions and kits.

Abstract: This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.

Abstract: This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.

Abstract: This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.

Abstract: This invention provides for a method for monitoring allograft rejection in a transplant recipient which includes: (a) obtaining peripheral blood lymphocytes from the recipient; (b) incubating the lymphocytes with at least one synthetic allopeptide which corresponds to an immunogenic hypervariable epitope of a mismatched donor HLA-DR antigen under suitable conditions, and (c) contacting the incubate with a marker for T-cell activation to determine whether or not the incubate contains activated T-cells, thereby monitoring allograft rejection in the recipient.

Abstract: This invention provides a purified new differentiation antigen, designated NDA4, associated with the growth and proliferation of activated B lymphocytes and characterized by a molecular weight of about 46,000 daltons.The invention also provides an antibody capable of specifically forming a complex with purified NDA4, and a hybridoma which produces a monoclonal antibody that specifically recognizes the isolated NDA4.The invention also pertains to a method for dectecting B cells or helper T cells, each of which has a B cell growth factor receptor, which comprises contacting a sample which contains B cells or helper T cells with substances capable of forming complexes with the B cell growth factor receptors so as to form cellular complexes between the substances and the B cell growth factor receptors, and detecting such cellular complexes.

Abstract: This invention provides a purified new differentiation antigen, designated NDA.sub.3, associated with the growth and proliferation of activated B lymphocytes and characterized by a molecular weight of about 36,000 daltons.The invention also provides an antibody capable of specifically forming a complex with purified NDA.sub.3. Another aspect of the invention provides a hybridoma which produces a monoclonal antibody that specifically recognizes the isolated NDA.sub.3.The invention also pertains to a method for detecting B cells or helper T cells, each of which has a B cell growth factor receptor, which comprises contacting a sample which contains B cells or helper T cells with substances capable of forming complexes with the B cell growth factor receptors so as to form cellular complexes between the substances and the B cell growth factor receptors, and detecting such cellular complexes.

Abstract: A late differentiation antigen (LDA.sub.1) expressed by activated helper cells is described. LDA.sub.1 is a membrane protein recognized by a monoclonal antibody produced by immunizing mice with an alloreactive human T cell clone with helper function. LDA.sub.1 is expressed by helper T cells optionally 9 days after activation. Anti-LDA.sub.1 monoclonal antibody blocks T cell enhancement of B-cell immunoglobulin production. Thus, LDA.sub.1 is associated with helper T cell effector function. Methods of diagnosis and therapy based upon LDA.sub.1 are also described.

Abstract: Late differentiation antigens (LDA.sub.1 and LDA.sub.2) expressed by activated helper cells are described. LDA.sub.1 and LDA.sub.2 are membrane proteins recognized by monoclonal antibodies produced by immunizing mice with alloreactive human T cell clones with helper function. LDA.sub.1 and LDA.sub.2 are expressed by helper T cells. LDA.sub.1 monoclonal antibody and LDA.sub.2 monoclonal antibody block T cell enhancement of B cell immunoglobulin production. Thus, LDA.sub.1 and LDA.sub.2 are associated with helper T cell effector function. Methods of diagnosis and therepy based upon LDA.sub.1 and LDA.sub.2 are also described.